1807503-92-9 Usage
Description
Bromo-PEG2-acid is a PEG linker containing a bromide group and a terminal carboxylic acid. The hydrophilic PEG spacer increases solubility in aqueous media. The bromide (Br) is a very good leaving group for nucleophilic substitution reactions. The terminal carboxylic acid can react with primary amine groups in the presence of activators (e.g., EDC or HATU) to form a stable amide bond.
Uses
Used in Chemical Biology and Medicinal Chemistry:
Bromo-PEG2-acid is used as a heterobifunctional, PEGylated crosslinker for bioconjugation or as a building block for the synthesis of small molecules, conjugates of small molecules and/or biomolecules, or other tool compounds that require ligation. This is due to its hydrophilic PEG linker, which facilitates solubility in biological applications.
Used in Targeted Protein Degradation:
Bromo-PEG2-acid is used as a component in the synthesis of proteolysis-targeting chimeras (PROTAC) molecules for targeted protein degradation. The bromo group at one end and the carboxyl group at the other end enable the formation of stable bonds with target proteins, leading to their degradation.
Used in Antibody-Drug Conjugates (ADCs):
Bromo-PEG2-acid is used as a linker in the development of antibody-drug conjugates (ADCs). Its ability to form stable amide bonds with primary amine groups allows for the attachment of cytotoxic drugs to antibodies, enabling targeted delivery to cancer cells and reducing side effects on healthy cells.
Check Digit Verification of cas no
The CAS Registry Mumber 1807503-92-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,8,0,7,5,0 and 3 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1807503-92:
(9*1)+(8*8)+(7*0)+(6*7)+(5*5)+(4*0)+(3*3)+(2*9)+(1*2)=169
169 % 10 = 9
So 1807503-92-9 is a valid CAS Registry Number.
1807503-92-9Relevant articles and documents
PCSK9 ANTAGONIST COMPOUNDS
-
Page/Page column 65; 66, (2021/03/05)
Disclosed are compounds of Formula (A), or a pharmaceutically acceptable salt thereof: where A, X, R1, and R2 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula (I) or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.
